UKOF 2018 | Recent trials in advanced prostate cancer: STAMPEDE and AdRad

Joe O’Sullivan, MD, of Queen’s University Belfast, Belfast, UK, speaks from the UK Oncology Forum (OF) 2018, held in Liverpool, UK, regarding developments in the treatment of advanced prostate cancer. He discusses the STAMPEDE trial (NCT00268476), exploring the effect of systemic therapies, such as docetaxel and abiraterone, on patients with advanced metastatic prostate cancer that is responsive to hormone therapy. Prof. O’Sullivan also mentions the AdRad trial (NCT00653848), which investigated the effect of radiotherapy on patients with de novo metastatic prostate cancer.